open access
Association between TSH suppression therapy and type 2 deiodinase gene polymorphism in differentiated thyroid carcinoma
Affiliations- Department of Otolaryngology Head and Neck Surgery, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
- Department of Ultrasound in Medicine, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
open access
Abstract
Introduction: Oral levothyroxine (L-T4) suppression of thyroid-stimulating hormone (TSH) levels is the most commonly used clinical approach to manage and treat patients after thyroid cancer surgery. This study aimed to investigate the association between TSH suppression therapy and type 2 deiodinase gene (DIO2) polymorphism in differentiated thyroid carcinoma (DTC).
Material and methods: A total of 240 patients with DTC who received total thyroidectomy (TT; 120) and hemithyroidectomy (HT; 120) were enrolled in this study. The serum TSH, free triiodothyronine (FT3), and free thyroxine (FT4) levels were detected using an automatic serum immune analyser and electrochemiluminescence immunoassay. Based on the results of DIO2 gene detection, 3 genotypes of Thr92Ala were detected.
Results: The serum TSH levels were inhibited after oral L-T4 treatment, but the proportion of patients who reached the TSH suppression standard in the hemithyroidectomy group was higher than in the total thyroidectomy group. After TSH suppression treatment, serum FT4 levels were increased in both total thyroidectomy and hemithyroidectomy. The difference in serum TSH, FT3, and FT4 levels was associated with different genotypes, and patients with high cytosine cytosine (CC) genotypes may have difficulty meeting the TSH suppression criteria.
Conclusions: Patients who underwent total thyroidectomy exhibited higher postoperative serum FT4 levels than patients in the hemithyroidectomy group after TSH suppression therapy. The Thr92Ala polymorphism of type 2 deiodinase (D2) was associated with TSH suppression therapy.
Abstract
Introduction: Oral levothyroxine (L-T4) suppression of thyroid-stimulating hormone (TSH) levels is the most commonly used clinical approach to manage and treat patients after thyroid cancer surgery. This study aimed to investigate the association between TSH suppression therapy and type 2 deiodinase gene (DIO2) polymorphism in differentiated thyroid carcinoma (DTC).
Material and methods: A total of 240 patients with DTC who received total thyroidectomy (TT; 120) and hemithyroidectomy (HT; 120) were enrolled in this study. The serum TSH, free triiodothyronine (FT3), and free thyroxine (FT4) levels were detected using an automatic serum immune analyser and electrochemiluminescence immunoassay. Based on the results of DIO2 gene detection, 3 genotypes of Thr92Ala were detected.
Results: The serum TSH levels were inhibited after oral L-T4 treatment, but the proportion of patients who reached the TSH suppression standard in the hemithyroidectomy group was higher than in the total thyroidectomy group. After TSH suppression treatment, serum FT4 levels were increased in both total thyroidectomy and hemithyroidectomy. The difference in serum TSH, FT3, and FT4 levels was associated with different genotypes, and patients with high cytosine cytosine (CC) genotypes may have difficulty meeting the TSH suppression criteria.
Conclusions: Patients who underwent total thyroidectomy exhibited higher postoperative serum FT4 levels than patients in the hemithyroidectomy group after TSH suppression therapy. The Thr92Ala polymorphism of type 2 deiodinase (D2) was associated with TSH suppression therapy.
Keywords
differentiated thyroid carcinoma; TSH; DIO2; Thr92Ala; genotypes
About this articleTitle
Association between TSH suppression therapy and type 2 deiodinase gene polymorphism in differentiated thyroid carcinoma
Journal
Issue
Article type
Original paper
Pages
408-413
Published online
2023-06-20
Page views
838
Article views/downloads
283
DOI
Pubmed
Bibliographic record
Endokrynol Pol 2023;74(4):408-413.
Keywords
differentiated thyroid carcinoma
TSH
DIO2
Thr92Ala
genotypes
Authors
Xiaoke Zheng
Lichang Zhong
Tianjiao Zhou
Feng Zhao
Bin Chen
References (25)- Cao W, Chen HD, Yu YW, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl). 2021; 134(7): 783–791.
- Xu Y, Huang K, Huang P, et al. Benefits and harms of hemithyroidectomy, total or near-total thyroidectomy in 1-4 cm differentiated thyroid cancer. Clin Endocrinol (Oxf). 2021; 95(4): 668–676.
- Zheng W, Rui Z, Wang X, et al. The Influences of TSH Stimulation Level, Stimulated Tg Level and Tg/TSH Ratio on the Therapeutic Effect of I Treatment in DTC Patients. Front Endocrinol (Lausanne). 2021; 12: 601960.
- Gullo D, Latina A, Frasca F, et al. Levothyroxine monotherapy cannot guarantee euthyroidism in all athyreotic patients. PLoS One. 2011; 6(8): e22552.
- Kim JD, Leyva S, Diano S. Hormonal regulation of the hypothalamic melanocortin system. Front Physiol. 2014; 5: 480.
- Gondou A, Toyoda N, Nishikawa M, et al. Effect of nicotine on type 2 deiodinase activity in cultured rat glial cells. Endocr J. 1999; 46(1): 107–112.
- Cicatiello AG, Di Girolamo D, Dentice M. Metabolic Effects of the Intracellular Regulation of Thyroid Hormone: Old Players, New Concepts. Front Endocrinol (Lausanne). 2018; 9: 474.
- St Germain DL, Galton VA, Hernandez A. Minireview: Defining the roles of the iodothyronine deiodinases: current concepts and challenges. Endocrinology. 2009; 150(3): 1097–1107.
- von Hafe M, Neves JS, Vale C, et al. The impact of thyroid hormone dysfunction on ischemic heart disease. Endocr Connect. 2019; 8(5): R76–R90.
- Guerra A, Sapio MR, Carrano M, et al. Prevalence of Dio2(T92A) polymorphism and its association with thyroid autoimmunity. J Endocrinol Invest. 2013; 36(5): 303–306.
- Maino F, Cantara S, Forleo R, et al. Clinical significance of type 2 iodothyronine deiodinase polymorphism. Expert Rev Endocrinol Metab. 2018; 13(5): 273–277.
- Janowska M, Potocka N, Paszek S, et al. Evaluation of the association between angiotensin converting enzyme insertion/deletion polymorphism and the risk of endometrial cancer in and characteristics of Polish women. Adv Clin Exp Med. 2020; 29(5): 581–585.
- Baksi S, Pradhan A. Thyroid hormone: sex-dependent role in nervous system regulation and disease. Biol Sex Differ. 2021; 12(1): 25.
- Zhang X, Sun J, Han W, et al. The Type 2 Deiodinase Thr92Ala Polymorphism Is Associated with Worse Glycemic Control in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. J Diabetes Res. 2016; 2016: 5928726.
- Torlontano M, Durante C, Torrente I, et al. Type 2 deiodinase polymorphism (threonine 92 alanine) predicts L-thyroxine dose to achieve target thyrotropin levels in thyroidectomized patients. J Clin Endocrinol Metab. 2008; 93(3): 910–913.
- Wang TS, Sosa JA. Thyroid surgery for differentiated thyroid cancer - recent advances and future directions. Nat Rev Endocrinol. 2018; 14(11): 670–683.
- Heemstra KA, Hamdy NAT, Romijn JA, et al. The effects of thyrotropin-suppressive therapy on bone metabolism in patients with well-differentiated thyroid carcinoma. Thyroid. 2006; 16(6): 583–591.
- Grani G, Ramundo V, Verrienti A, et al. Thyroid hormone therapy in differentiated thyroid cancer. Endocrine. 2019; 66(1): 43–50.
- Sasson M, Kay-Rivest E, Shoukrun R, et al. The T4/T3 quotient as a risk factor for differentiated thyroid cancer: a case control study. J Otolaryngol Head Neck Surg. 2017; 46(1): 28.
- Castagna MG, Dentice M, Cantara S, et al. DIO2 Thr92Ala Reduces Deiodinase-2 Activity and Serum-T3 Levels in Thyroid-Deficient Patients. J Clin Endocrinol Metab. 2017; 102(5): 1623–1630.
- Marcondes AA, Gomez TGB, Ravache TT, et al. Assessment of children in the autistic spectrum disorder that carry the Thr92Ala-DIO2 polymorphism. J Endocrinol Invest. 2021; 44(8): 1775–82.
- Kang YE, Kang YMi, Park B, et al. Type 2 deiodinase Thr92Ala polymorphism is associated with a reduction in bone mineral density: A community-based korean genome and epidemiology study. Clin Endocrinol (Oxf). 2020; 93(3): 238–247.
- Wang X, Chen K, Zhang C, et al. The Type 2 Deiodinase Thr92Ala Polymorphism Is Associated with Higher Body Mass Index and Fasting Glucose Levels: A Systematic Review and Meta-Analysis. Biomed Res Int. 2021; 2021: 9914009.
- He B, Li J, Wang G, et al. Association of genetic polymorphisms in the type II deiodinase gene with bipolar disorder in a subset of Chinese population. Prog Neuropsychopharmacol Biol Psychiatry. 2009; 33(6): 986–990.
- Wouters HJ, van Loon HCM, van der Klauw MM, et al. No Effect of the Thr92Ala Polymorphism of Deiodinase-2 on Thyroid Hormone Parameters, Health-Related Quality of Life, and Cognitive Functioning in a Large Population-Based Cohort Study. Thyroid. 2017; 27(2): 147–155.
